Searchable abstracts of presentations at key conferences in endocrinology

ea0020p432 | Diabetes and Cardiovascular | ECE2009

Can testosterone therapy be included into diabetes treatment in men with metabolic syndrome and hypogonadism?

Kalinchenko Svetlana , Saad Farid , Mskhalaya George , Tishova Yuliya

Background: In 1998 the UKPDS study showed that over 10 years of observation there were no significant changes in haemoglobin A1c (HbA1c) in intensive insulin therapy group compared with conventional therapy group. Therefore, we still need new options to treat diabetes. Diabetes mellitus type 2 (DMT2), is one of the MS components. Obesity leads to insulin resistance (IR) and DMT2. Androgen deficiency (AD) is well-known factor to predict the development of diabetes.<p class...

ea0020p502 | Obesity and Metabolism | ECE2009

Prevalence of the metabolic syndrome in men with late-diagnosed Klinefelter syndrome

Gusakova Daria , Kalinchenko Svetlana , Mskhalaya George , Tishova Yuliya

Introduction: Klinefelter syndrome (KS) is the most common sex-chromosome disorder with a prevalence of 1 in every 660 men, but only 25% of the expected number of patients are diagnosed. It is also one of the most common endocrine disorders, and takes the third place after diabetes mellitus and thyroid gland diseases. KS is one of the most frequent causes of hypogonadism in men. It is known that hypogonadism in men has been found to be an independent risk factor for developmen...

ea0020p515 | Endocrine Disruptors | ECE2009

Why does Klinefelter syndrome often remain undiagnosed?

Gusakova Daria , Kalinchenko Svetlana , Mskhalaya George , Tishova Yuliya

Introduction: Underdiagnosis and delayed diagnosis of Klinefelter syndrome (KS) is a major problem. KS is revealed only in 25% of the expected amount of patients. Early diagnosis facilitates prevention of the long-term consequences of hypogonadism and permits to begin testosterone-replacement therapy opportunely. The ‘prototypic’ patient with KS has traditionally been described as tall, thin, with long hips, narrow shoulders, having gynecomastia, small testes, sparse...

ea0020p647 | Reproduction | ECE2009

Spermatogenesis in men with late-onset hypogonadism, receiving testosterone-gel

Mskhalaya George , Tishova Yulia , Vadov Vadim , Gusakova Dariya , Kalinchenko Svetlana

The prevalence of LOH among middle-aged men, who want to have kids, is increasing. According to HIM study (Mulligan T, Frick MF 2006), the prevalence of LOH is 34% in men, aged 45–54. There are 3 wide-spread forms of testosterone treatment of LOH: oral, i/m forms, and gels. Oral forms of treatment are known to have a rather weak effect. I/m forms of testosterone treatment have a significant negative effect on spermatogenesis down to azoospermia, causing decrease in LH and...

ea0020p665 | Reproduction | ECE2009

Our experience in treatment of infertility in patients with Klinefelter syndrome (mosaic karyotype 46,XY/47,XXY)

Vinogradov Igor , Kalinchenko Svetlana , Mskhalaya George , Gusakova Dariya , Afanasjeva Lubov

Introduction: Until 1996, men with Klinefelter syndrome (KS) were considered to be infertile, but with the development of testicular sperm extraction (TESE) and intracytoplasmatic sperm injection (ICSI) it is now possible to extract viable spermatozoa from the testes using surgical biopsy for the future injection into an ovum. A minority of men with KS have viable sperm in their ejaculate and might, therefore, be able to provide native sperm for ICSI.Mat...

ea0016p208 | Diabetes and cardiovascular diseases | ECE2008

May testosterone therapy be the key to metabolic syndrome (MS) treatment in men?

Tishova Yuliya , Mskhalaya George , Saad Farid , Kalinchenko Svetlana

Background: Impaired glycaemic control, resulting in diabetes mellitus type 2 (DMT2), is one of the MS components. In 1998 the UKPDS study showed that over 10 years of observation there were no significant changes in haemoglobin A1c (HbA1c) in intensive insulin therapy group compared with conventional therapy group. Therefore, we still need new options to treat DMT2. Testosterone is well-known for it’s lipolytic activity; obesity leads to insulin resistance and DMT2.<...

ea0022p523 | Male reproduction | ECE2010

The Moscow Study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count

Mskhalaya George , Kalinchenko Svetlana , Tishova Yuliya , Saad Farid , Gooren Louis J G , Giltay Erik J

Background: For many years testosterone therapy in men was considered to be a risk factor for increasing the PSA level and prostate volume as well as blood count parameters. Objective was to investigate the influence of testosterone therapy on prostate and blood count in men with metabolic syndrome and hypogonadism.Methods: In a randomized, placebo-controlled, double-blind, phase III trial (ClinicalTrials.gov identifier: NCT00696748), 184 men suffering f...

ea0022p524 | Male reproduction | ECE2010

Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow Study

Giltay Erik J , Tishova Yuliya , Mskhalaya George , Gooren Louis J G , Saad Farid , Kalinchenko Svetlana

Context: Low testosterone level in men is associated with the metabolic syndrome (MetS) as well as with depressive symptoms, low vitality and sexual dysfunction.Objective: To assess the effects of testosterone administration on these subjective symptoms, which have not extensively been studied in hypogonadal men with the MetS. Design: randomized, placebo-controlled trial. Setting: academic, ambulatory, referral centre. Patients: 184 men suffering from bo...

ea0022p681 | Obesity | ECE2010

The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the metabolic syndrome components and body composition

Tishova Yuliya , Kalinchenko Svetlana , Mskhalaya George , Saad Farid , Gooren Louis J G , Giltay Erik J

Background: Metabolic syndrome has a high prevalence in male population, leading to the high rate of cardiovascular disease and mortality. Numerous studies show that low androgen levels in men are associated with the metabolic syndrome. This study tested whether normalization of testosterone levels improves metabolic dysregulations and body composition.Methods: In a randomized, placebo-controlled, double-blind, phase III trial (ClinicalTrials.gov identif...

ea0022p682 | Obesity | ECE2010

Effects of parenteral testosterone undecanoate administration on inflammatory markers: the Moscow study

Kalinchenko Svetlana , Tishova Yuliya , Mskhalaya George , Saad Farid , Gooren Louis J G , Giltay Erik J

Background: Numerous studies (among which, studies of androgen deprivation in men with prostate cancer) show that low androgen levels in men are associated with the metabolic syndrome. Obesity and particularly visceral fat excess is associated with pro-thrombotic and pro-inflammatory states as well. This study tested whether normalization of testosterone levels improves markers of inflammation.Methods: In a randomized, placebo-controlled, double-blind, p...